TMB has been found highly correlated with the activity of anti–PD-1 therapies across multiple cancers [15] and it has been approved by the United States Food and Drug Administration (FDA) as a criterion for pembrolizumab treatment across different tumor types. This evidence concerns the gene PDCD1 and neoplasm.